

## Special Issue

# Targeting Human Glioblastoma Stem-Like Cells (GSCs)

### Message from the Guest Editors

Glioblastoma remains a virtually incurable disease with a dismal prognosis for patients and a plethora of open questions. The current standard therapy consists of surgery, radiochemotherapy and, in some cases, the application of tumor-treating fields. Even though promising new therapeutic avenues are underway, novel and especially directed approaches are direly needed. In particular, much research in recent years showed that GBM cells can obtain a highly plastic and dynamic phenotype, which gives these cells a stem-like state that enables them to out-live conventional therapies and ultimately replenish the tumor. In order to collectively present and aggregate recent developments in precision oncology, we invite both original research and review articles highlighting key aspects of glioblastoma biology, with a special focus on stem-like cells.

---

### Guest Editors

Dr. Benedikt Linder

Experimental Neurosurgery, Neuroscience Center, Goethe-University Frankfurt, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany

Dr. Ander Matheu

Cellular Oncology Group, Biodonostia Health Research Institute, E-20014 San Sebastian, Spain

---

### Deadline for manuscript submissions

closed (30 June 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/126770](https://mdpi.com/si/126770)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)